000285729 001__ 285729
000285729 005__ 20260320144416.0
000285729 0247_ $$2doi$$a10.1007/s00401-026-02998-4
000285729 0247_ $$2pmid$$apmid:41851356
000285729 0247_ $$2ISSN$$a0001-6322
000285729 0247_ $$2ISSN$$a1432-0533
000285729 037__ $$aDZNE-2026-00286
000285729 041__ $$aEnglish
000285729 082__ $$a610
000285729 1001_ $$0P:(DE-2719)9003742$$aSaleem, Tayyaba$$b0$$eFirst author$$udzne
000285729 245__ $$aA distinct tau oligomer strain defines the molecular and proteomic landscape of rapidly progressive Alzheimer's disease.
000285729 260__ $$aHeidelberg$$bSpringer$$c2026
000285729 3367_ $$2DRIVER$$aarticle
000285729 3367_ $$2DataCite$$aOutput Types/Journal article
000285729 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1774014011_12445
000285729 3367_ $$2BibTeX$$aARTICLE
000285729 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285729 3367_ $$00$$2EndNote$$aJournal Article
000285729 520__ $$aRapidly progressive Alzheimer's disease (rpAD) is a rare subtype with rapid decline, but its molecular underpinnings remain poorly defined. Here, brain-derived tau oligomers (TauO) were systematically compared across nondemented controls, slowly progressive AD (spAD), and rpAD to test whether subtype-specific TauO signatures align with clinical aggressiveness. TauO were immunoprecipitated from frontal cortex using T22 antibody and characterized by Western blotting, transmission electron microscopy, label-free quantitative proteomics, and SH-SY5Y toxicity assays, complemented by longitudinal analysis of tau phosphorylation in inoculated 3xTg AD mice. T22-positive high-molecular-weight TauO were successfully enriched from all groups, where rpAD TauO exhibited compact, densely packed oligomers under TEM and the highest phosphorylation at pS396 and pS422, exceeding both spAD and controls (p ≤ 0.0327). In 3xTg mice, pS396 showed an early increase followed by a late decline, consistent with dynamic shifts in tau solubility during disease evolution. Brain-derived TauO from spAD and rpAD, but not recombinant tau monomers or control-derived TauO, significantly reduced SH-SY5Y cell viability. Proteomic profiling identified 2388 TauO-associated proteins, including a shared 556-protein core and a striking expansion of rpAD-unique interactors (n = 1101). In controls and spAD, the core TauO interactome was enriched for translation, proteostasis, mitochondrial respiration, and vesicle-trafficking pathways, whereas these modules were absent in rpAD. Instead, rpAD TauO showed selective enrichment of aldehyde detoxification, amino-acid and carbon metabolism, and actin-regulatory modules, alongside increased association of SERPINA1, ALDH9A1, MAPRE3, DPYSL2, DPYSL3, and NFASC and reduced coupling to mitochondrial (MRPL17) and complement (C9) components. These convergent structural, post-translational, toxic, and interactome changes indicate that rpAD is defined by a biochemically distinct TauO species embedded in a metabolic and cytoskeleton-focused network, providing a mechanistic framework for its aggressive clinical course and a basis for subtype-specific biomarker and therapeutic strategies.
000285729 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285729 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285729 650_7 $$2Other$$aAlzheimer’s disease
000285729 650_7 $$2Other$$aMitochondrial dysfunction
000285729 650_7 $$2Other$$aProtein aggregation
000285729 650_7 $$2Other$$aProteomics
000285729 650_7 $$2Other$$aRapidly progressive Alzheimer’s disease
000285729 650_7 $$2Other$$aTau oligomers
000285729 650_7 $$2NLM Chemicals$$atau Proteins
000285729 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000285729 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000285729 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000285729 650_2 $$2MeSH$$atau Proteins: metabolism
000285729 650_2 $$2MeSH$$aAnimals
000285729 650_2 $$2MeSH$$aHumans
000285729 650_2 $$2MeSH$$aMice
000285729 650_2 $$2MeSH$$aProteomics
000285729 650_2 $$2MeSH$$aMice, Transgenic
000285729 650_2 $$2MeSH$$aMale
000285729 650_2 $$2MeSH$$aDisease Progression
000285729 650_2 $$2MeSH$$aFemale
000285729 650_2 $$2MeSH$$aBrain: metabolism
000285729 650_2 $$2MeSH$$aBrain: pathology
000285729 650_2 $$2MeSH$$aAged
000285729 650_2 $$2MeSH$$aCell Line, Tumor
000285729 650_2 $$2MeSH$$aPhosphorylation
000285729 650_2 $$2MeSH$$aDisease Models, Animal
000285729 650_2 $$2MeSH$$aAged, 80 and over
000285729 7001_ $$aMöbius, Wiebke$$b1
000285729 7001_ $$0P:(DE-2719)9000287$$aSchmitz, Matthias$$b2$$udzne
000285729 7001_ $$0P:(DE-HGF)0$$ada Silva Correia, Angela$$b3
000285729 7001_ $$aThomas, Carolina$$b4
000285729 7001_ $$0P:(DE-2719)9001944$$aCanaslan, Sezgi$$b5
000285729 7001_ $$0P:(DE-2719)2812183$$aHermann, Peter$$b6
000285729 7001_ $$0P:(DE-2719)9001986$$aGoebel, Stefan$$b7
000285729 7001_ $$0P:(DE-2719)9000358$$aZafar, Saima$$b8$$udzne
000285729 7001_ $$aRoot, Elisabeth$$b9
000285729 7001_ $$aStadelmann, Christine$$b10
000285729 7001_ $$aAndreoletti, Olivier$$b11
000285729 7001_ $$aHoppert, Michael$$b12
000285729 7001_ $$aFleming Outeiro, Tiago$$b13
000285729 7001_ $$aFerrer, Isidre$$b14
000285729 7001_ $$0P:(DE-2719)9001558$$aYounas, Neelam$$b15
000285729 7001_ $$0P:(DE-2719)2000058$$aZerr, Inga$$b16$$eLast author$$udzne
000285729 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-026-02998-4$$gVol. 151, no. 1, p. 27$$n1$$p27$$tActa neuropathologica$$v151$$x0001-6322$$y2026
000285729 8564_ $$uhttps://pub.dzne.de/record/285729/files/DZNE-2026-00286.pdf$$yRestricted
000285729 8564_ $$uhttps://pub.dzne.de/record/285729/files/DZNE-2026-00286.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285729 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003742$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000285729 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000287$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000285729 9101_ $$0I:(DE-588)1065079516$$6P:(DE-HGF)0$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000285729 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001944$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000285729 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812183$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000285729 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001986$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000285729 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000358$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000285729 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001558$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000285729 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000058$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b16$$kDZNE
000285729 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285729 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-11$$wger
000285729 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-11$$wger
000285729 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000285729 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000285729 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000285729 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-11
000285729 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000285729 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-11
000285729 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-11
000285729 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000285729 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000285729 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2022$$d2024-12-11
000285729 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-11
000285729 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-11
000285729 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bACTA NEUROPATHOL : 2022$$d2024-12-11
000285729 9201_ $$0I:(DE-2719)1440011-1$$kAG Zerr$$lTranslational Studies and Biomarker$$x0
000285729 9201_ $$0I:(DE-2719)1440015$$kClinical Dementia Research (Göttingen)$$lClinical Dementia Research (Göttingen)$$x1
000285729 980__ $$ajournal
000285729 980__ $$aEDITORS
000285729 980__ $$aVDBINPRINT
000285729 980__ $$aI:(DE-2719)1440011-1
000285729 980__ $$aI:(DE-2719)1440015
000285729 980__ $$aUNRESTRICTED